Spotlight Poster Discussion: "Combined inhibition of CDK4/6 and AKT (LAR subtype)"

Spotlight Poster Discussion: "Combined inhibition of CDK4/6 and AKT (LAR subtype)"Подробнее

Spotlight Poster Discussion: "Cardiotoxi"Подробнее

Biomarkers to help predict response to CDK4/6 inhibitorsПодробнее

Expert discussion on CDK 4/6 inhibition in breast cancerПодробнее

Case 2: Choosing a CDK4/6 Inhibitor in ER+ Breast CancerПодробнее

Conversations with Skin Award WinnersПодробнее

Spotlight Poster Discussion: "Evaluating emerging and established biomarkers"Подробнее

CDK4/6 inhibitors: Can they be used for TNBC or HER2+ breast cancer?Подробнее

Spotlight Poster Discussion 14 - Clinical translational updates in invasive lobular carcinomaПодробнее

Selecting Agents in CDK4/6 Inhibition for HR+ mBCПодробнее

CDK4/6 Inhibition’s Role in HR+ Metastatic Breast CancerПодробнее

Highlights from SABCS 2020: New data on CDK4/6 inhibitors, omitting chemotherapy and radiotherapyПодробнее

CDK4/6 Inhibition in Breast CancerПодробнее

Segment 4: Panel Case DiscussionПодробнее

HR+ mBC: Factors in Selecting CDK4/6 InhibitionsПодробнее

Session 2: Considerations Selecting ART | EnglishПодробнее

Segment 4: Panel Case DiscussionsПодробнее